NeuroPace (NPCE) Earnings Call Presentation

Financial Performance & Growth - NeuroPace's revenue grew by 24% to $22.5 million in Q1 2025[10] - Excluding NAUTILUS study implants in Q1 2024, RNS System revenue grew by 29%[10] - The company anticipates revenue between $93 million and $97 million for 2025, representing a 16%-21% year-over-year growth[71] - Gross margin for Q1 2025 was 77%[71] - Operating expenses for Q1 2025 were $22.5 million[71] - Total cash balance was $66.3 million as of March 31, 2025[69] Market Opportunity & Expansion - The total U S addressable market is >$55 billion[9] - The annual core market opportunity within Comprehensive Epilepsy Centers (CECs) is >$2 billion[9] - Approximately 40% of Drug-Resistant Epilepsy (DRE) patients have generalized epilepsy[57, 61, 66] - Project CARE aims to expand access to the RNS System outside of Level 4 CECs, targeting an additional 1,800 epileptologists and all functional neurosurgeons[53, 61, 66]